Consumers who take GLP-1 drugs might switch what they eat, but they largely spend the same amount of money on CPG food and ...

Shares in Hims Hers Health Inc (NYSE:HIMS) fell Friday after Citigroup (NYSE:C) analysts downgraded the stock to Sell/High ...

New findings on semaglutide and tirzepatide published in 2024 revealed that the medications may have benefits beyond lowering glucose levels and body weight.At the Cardiometabolic Health Congress in ...

GLP-1 drugs, widely used for treating metabolic disorders, often face issues with long term tolerability, leading to side effects such as sarcopenia and bone density loss. These complications ...

The round is one of Europe’s largest-ever biotech VC deals, signalling investor appetite for the booming weight loss market.

The best semaglutide dose for weight loss varies according to your starting weight, risks, and stage of treatment. Read to ...

Maridebart cafraglutide, a novel injectable GLP-1 receptor agonist/GIP receptor antagonist, reduced body weight by up to ...

With three meds approved for weight management and several on the way, these may make a dent in the obesity epidemic.

Metabolic medicines dominated life sciences headlines in 2024, a trend expected to continue into the new year. Other things ...

As usage of the medications increases, Circana research indicates deli and produce could be bright spots for spending.

The evolution of AI, more limited-time product offerings and GLP-1 use for weight loss are among the issues expected to play ...

Political and economic uncertainty hangs over the industry, while major bets on metabolic and immune disease drug research are set to play out.